Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
暂无分享,去创建一个
Z. Sápi | C. Bödör | J. Pápay | M. Csóka | E. Zajta | K. Dezső | E. Varga | K. Mudra | L. Hegyi | Catherine Cervi | G. Bedics
[1] Si Li,et al. Characterization of NTRK gene fusion events in solid tumors among Chinese patients. , 2021 .
[2] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[3] S. Bielack,et al. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] K. Bencardino,et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E. Lander,et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research , 2019, Nature Medicine.
[6] J. Sicklick,et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.
[7] C. Antonescu,et al. A novel group of spindle cell tumors defined by S100 and CD34 co‐expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes , 2018, Genes, chromosomes & cancer.
[8] Jessica L. Davis,et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas , 2018, Cancer.
[9] D. Orbach,et al. Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report , 2018, Virchows Archiv.
[10] A. Drilon,et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.
[11] Jessica L. Davis,et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.
[12] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[13] C. Antonescu,et al. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma , 2017, The American journal of surgical pathology.
[14] Ryohei Katayama,et al. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers , 2017, Molecular Cancer Therapeutics.
[15] Narasimhan P. Agaram,et al. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors , 2016, The American journal of surgical pathology.
[16] C. Mackall,et al. Current approach to pediatric soft tissue sarcomas. , 2009, The oncologist.
[17] N. Sebire,et al. Angiosarcoma of skull base in a 1-year-old child--a case report. , 2009, International journal of pediatric otorhinolaryngology.
[18] K. Thornton,et al. Pediatric soft tissue sarcomas. , 2008, The Surgical clinics of North America.
[19] A. Ferrari,et al. Malignant vascular tumors in children and adolescents: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. , 2002, Medical and pediatric oncology.
[20] M. Skup. Neurotrophins : evolution of concepts on rational therapeutic approaches , 2018 .
[21] S. Skaper. Neurotrophic Factors: An Overview. , 2018, Methods in molecular biology.
[22] M. Chao,et al. Trk receptors. , 2014, Handbook of experimental pharmacology.
[23] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[24] D. C. Henckel,et al. Case report. , 1995, Journal.